Medical/Pharmaceuticals
Lianhua Qingwen Sent to People for Covid-19 Containment by Cambodian Government
PHNOM PENH, Cambodia, Nov. 10, 2021 /PRNewswire/ -- On Sunday, 600 local families in Veal Veaeng District, Pursat Province,Cambodia, got Lianhua Qingwen Capsules, produced by Yiling Pharmaceutical, from Suy Sem, the Cambodian Minister of Mines and Energy, also president of the Cambodian central ...
2021-11-10 20:07
3054
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
* The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa * Jumpcan will pay I-Mab for a total of up to RMB 2.016...
2021-11-10 17:30
2550
Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a ...
2021-11-10 17:00
1974
AffaMed Therapeutics Announces the Establishment of AffaMed Digital to Advance Digital Medicines
SHANGHAI, Nov. 10, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage therapeutic company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and ...
2021-11-10 15:00
3106
OMRON Launches World's Fastest CT X-ray Inspection with New VT-X750-V3 AXI System
KYOTO, Japan, Nov. 10, 2021 /PRNewswire/ -- OMRON Corporation based in Kyoto, Japan, has announced the development of a new VT-X750-V3 system, the world's fastest (*1) CT-type X-ray inspection device (*2) to date, and said it will be released globally onNovember 20. The VT-X750-V3 delivers advanc...
2021-11-10 14:00
1970
LifeWave Held Amplify Summer Summit 2021
TOKYO, Nov. 10, 2021 /PRNewswire/ -- LifeWave, a U.S.-based global health technology company, hosted a summer conference onAugust 21 and 22, 2021. The conference, dubbedAmplify, focused on LifeWave's products and the company's business opportunities. It was held virtually because of recommendatio...
2021-11-10 11:18
3289
Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, Nov. 10, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the approval of the Phase II clinical trial of ASC22 (Envafolimab) by China National Medical Products Administration (NMPA) for the proposed new indication of immune restoration/fu...
2021-11-10 08:30
3823
Smith+Nephew establishes its first Medical Education Centre for the Asia Pacific region in Singapore
LONDON, Nov. 10, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the
global medical technology business, today announces its first dedicated Medical
Education Centre to support customers across theAsia Pacific region.
2021-11-10 08:04
5863
Prenetics Announces Strong First Half 2021 Financial Results as Company Progresses Towards a U.S. Nasdaq Listing in Partnership with Artisan Acquisition Corp.
* Revenue reached US$136.5 million, up 1,039% year-over-year * Adjusted EBITDA was US$31.5 million, increased by US$34.6 million year-over-year * Prenetics has publicly filed a registration statement on Form F-4 with the SEC in connection with its proposed business combination with Artisan ...
2021-11-10 07:34
3041
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
* Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity * Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea, Nov. 9, 2021 /PRNewswire/ -- I-Mab ...
2021-11-09 21:05
3171
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-a...
2021-11-09 21:00
3687
Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative
MANASSAS, Va., Nov. 9, 2021 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of theApril...
2021-11-09 20:55
3276
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying vi...
2021-11-09 20:30
2564
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administr...
2021-11-09 19:00
2299
Regrowing Damaged Body Parts: How Osteopore, an Australian-listed Company, is Making it Accessible
SINGAPORE, Nov. 9, 2021 /PRNewswire/ -- Osteopore, an Australian and Singapore based leader in regenerative implants on a commercial scale, is developing technology that enables widespread adoption of tissue engineering. Despite the global average life expectancy rising by more than 6 years betwe...
2021-11-09 18:05
2339
Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting
SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-11-09 16:30
5088
Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery
SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285...
2021-11-09 10:47
3087
Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern
TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burden, today announced preclinical data...
2021-11-09 10:00
4137
Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study
HANGZHOU, China and SHAOXING, China, Nov. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the interim results of 44 chronic hepatitis B (CHB) patients from a Phase IIb trial of ASC22 (Envafolimab), a subcutaneously administered PD-L1 antibody (ClinicalTrials.gov Ide...
2021-11-09 08:33
4232
CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics
* The two sides will jointly develop up to three preclinical first-in-class or best-in-class next-generation antibody therapies, for which CStone would lead the design of the target combination based on the intended mechanism of action and DotBio will lead the design and engineering of the mole...
2021-11-09 08:05
5881
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 325 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 307 media titles]
2026-08-07 22:30Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 296 media titles]
2026-08-04 07:00
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 296 media titles]
2026-08-06 15:10
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 292 media titles]
2026-08-04 14:30
Most Read
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
2026-08-04 07:00
10449
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
8105
Singapore Good Soil Foundation Hosts Third Next Generation Philanthropy Leadership Program at the University of Hong Kong, Empowering the Next Generation of Global Changemakers
2026-08-02 02:09
7569
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
2026-08-04 06:00
6943
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
2026-08-04 14:30
6619